Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Upgraded by B. Riley

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by B. Riley to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on ARWR. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. Royal Bank Of Canada decreased their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Finally, TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 28th. Three analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $43.14.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $17.80 on Monday. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $27.34. The company has a 50 day moving average of $16.52 and a two-hundred day moving average of $15.92. The company has a market cap of $2.46 billion, a P/E ratio of -13.91, a P/E/G ratio of 25.55 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the prior year, the company posted ($1.38) EPS. On average, analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its position in Arrowhead Pharmaceuticals by 43.1% in the 4th quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company’s stock valued at $1,182,000 after buying an additional 18,933 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Arrowhead Pharmaceuticals by 13.3% during the 4th quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 1,759 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $651,000. Summit Investment Advisors Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock valued at $714,000 after purchasing an additional 803 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Arrowhead Pharmaceuticals by 13.0% during the 4th quarter. Barclays PLC now owns 312,560 shares of the biotechnology company’s stock valued at $5,876,000 after purchasing an additional 35,950 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.